Orticumab

Monoclonal antibody

Pharmaceutical compound

Orticumab (INN) is a human monoclonal antibody that is used as an anti-inflammatory agent and binds to oxLDL. It acts as an immunomodulator.^[1]

References

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Human	Burosumab Denosumab
Humanized	Blosozumab ^† Romosozumab

Human	Stamulumab ^†

Human	Abelacimab Alirocumab Ascrinvacumab ^§ Bentracimab ^† Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Marstacimab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse	Biciromab ^‡ Imciromab ^‡
Chimeric	Abciximab Volociximab
Humanized	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Concizumab Demcizumab Emicizumab Etaracizumab Faricimab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Human	Anti-amyloid drugs Aducanumab ^‡ Donanemab Gantenerumab ^† Lecanemab Erenumab Fasinumab ^† Fulranumab Opicinumab
Humanized	Bapineuzumab ^† Crenezumab ^† Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Semorinemab Solanezumab Tanezumab ^†

Humanized	Ranibizumab

Human	Bimagrumab Trevogrumab
Humanized	Domagrozumab Landogrozumab

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.